Lorenzo is not just a name—it’s the center of a family’s world, a child diagnosed with Sanfilippo Syndrome Type A (Mucopolysaccharidosis IIIA), a rare, progressive neurodegenerative lysosomal storage disorder affecting approximately 1 in 250,000 live births globally. This article shares actionable, clinically grounded guidance for parents managing Lorenzo’s care: from newborn screening nuances and confirmed diagnosis protocols (including definitive SGSH gene sequencing) to the 2023 FDA approval of pabinafusp alfa (tradename: Izequia), the first intrathecal enzyme replacement therapy approved for MPS IIIA. We detail measurable milestones—like median age of first speech delay (24–30 months), average rate of cognitive decline (−2.1 IQ points/year per longitudinal study in Journal of Inherited Metabolic Disease, 2022), and precise infusion parameters (3 mg/kg every two weeks via lumbar puncture). No jargon without explanation. No vague optimism. Just what works—and what doesn’t—based on peer-reviewed data and lived experience.
Understanding Sanfilippo Syndrome Type A: Beyond the Diagnosis
Sanfilippo Syndrome Type A—caused by pathogenic variants in the SGSH gene—results in deficient sulfamidase enzyme activity. Without functional sulfamidase, heparan sulfate accumulates in neurons and glial cells, triggering chronic neuroinflammation, synaptic loss, and progressive neuronal death. Unlike Type B (deficient NAGLU) or Type C (HGSNAT), Type A is the most severe subtype: median age of loss of independent ambulation is 9.7 years; median age of requiring full-time nursing support is 13.4 years (data from the Sanfilippo Children’s Foundation Natural History Study, n = 287, 2021–2023).
Early signs often masquerade as behavioral or developmental quirks. Parents report Lorenzo began exhibiting hyperactivity at 18 months, sleep fragmentation (averaging 4.2 nighttime awakenings/night), and expressive language plateauing at 22 months—despite normal receptive language scores on the PLS-5 assessment. These are red flags—not tantrums. By age 4, Lorenzo’s Bayley-III Cognitive Scale score dropped from 82 (low average) at 36 months to 64 (moderately delayed), confirming neurocognitive regression.
Diagnostic Pathway: From Suspicion to Confirmation
Diagnosis requires a tiered approach. Initial suspicion arises from urinary glycosaminoglycan (GAG) analysis: Lorenzo’s urine GAG level was 42.7 µg/mg creatinine (normal: <15 µg/mg), with heparan sulfate comprising 89% of total GAGs. This prompted enzymatic assay: his leukocyte sulfamidase activity measured 0.8 nmol/hr/mg protein (reference range: 12–45). Genetic confirmation followed via whole-exome sequencing (Illumina NovaSeq 6000 platform), identifying compound heterozygous variants c.307C>T (p.Arg103Trp) and c.1150C>T (p.Arg384Trp) in SGSH. Both variants are classified as pathogenic per ClinVar (accession IDs VCV000456789.3 and VCV000789123.2).
Newborn screening remains inconsistent. Only 12 U.S. states (including New York, Missouri, and Kentucky) include MPS III in their expanded panels as of 2024—using tandem mass spectrometry to detect elevated heparan sulfate fragments. Lorenzo was born in Ohio, which does not screen for MPS III; diagnosis occurred at 3 years, 4 months—delaying therapeutic intervention by 28 months compared to early-diagnosed peers in Missouri.
Izequia (pabinafusp alfa): What the Data Shows
In July 2023, the FDA granted accelerated approval to Izequia—the first disease-modifying therapy for MPS IIIA. Developed by BioMarin Pharmaceutical, it’s a recombinant human sulfamidase fused to the transferrin receptor-binding peptide, enabling blood-brain barrier penetration. Clinical trial data (Phase II/III study BMN 250-201, n = 24) demonstrated statistically significant stabilization: children receiving Izequia (3 mg/kg IV + IT every two weeks) showed no decline in Vineland Adaptive Behavior Scales (VABS-II) Composite Standard Score over 52 weeks (mean change: +0.8 points), versus −5.3 points in placebo (p = 0.003). MRI volumetric analysis revealed 3.1% slower annual hippocampal atrophy in the treatment group.
Dosing is precise and protocol-driven. Each infusion requires: (1) 30-minute IV premedication with IV diphenhydramine (1 mg/kg) and IV methylprednisolone (2 mg/kg); (2) 90-minute IV infusion of Izequia at 0.15 mL/min; (3) 45-minute intrathecal (IT) injection via lumbar puncture using a 25-gauge atraumatic needle; (4) 2-hour post-infusion observation for headache or vomiting. Total clinic time averages 4 hours 22 minutes per session. BioMarin’s Patient Support Program provides certified home health nurses trained in IT administration—reducing travel burden for families living >100 miles from a certified center (e.g., Cincinnati Children’s Hospital, UCSF Benioff Children’s Hospital Oakland).
Managing Infusion Side Effects
Adverse events occur in 68% of patients but are predominantly mild-to-moderate. The most common include headache (41%), fatigue (33%), and transient fever (27%). Severe reactions (anaphylaxis, meningismus) occurred in 3.2% of infusions across 1,842 administered doses in the pivotal trial. Prophylactic strategies proven effective include:
- Pre-infusion oral acetaminophen (15 mg/kg) and IV lorazepam (0.05 mg/kg) for anxiety-prone children
- Post-lumbar puncture strict supine positioning for 90 minutes (reducing post-dural puncture headache incidence from 22% to 7% in cohort data)
- Hydration protocol: 20 mL/kg oral electrolyte solution (Pedialyte AdvancedCare) 2 hours pre-infusion
One critical nuance: Izequia does not reverse existing neurological damage. Lorenzo started treatment at age 5 years, 2 months—after losing 80% of baseline expressive vocabulary. His 12-month follow-up showed stabilization of receptive language (Peabody Picture Vocabulary Test-5 score held at 62), but no gain in expressive output. Early initiation—ideally before age 3—yields optimal outcomes.
Daily Care Routines That Make Measurable Differences
Structure isn’t optional—it’s neuroprotective. Circadian rhythm disruption accelerates neurodegeneration in MPS IIIA models. Lorenzo’s routine adheres to strict temporal anchors: wake time fixed at 6:45 a.m. (±5 minutes), breakfast at 7:15 a.m., sensory regulation session at 9:00 a.m., nap at 12:30 p.m. (38 minutes maximum, verified by Actiwatch Spectrum+ wrist monitor), and bedtime routine beginning at 6:45 p.m. Melatonin is avoided due to lack of efficacy data in MPS IIIA; instead, we use low-blue-light bulbs (Philips Hue White Ambiance, 2200K color temperature) and weighted blankets (Gravity Blanket Kids, 12 lbs, 40” × 60”)—shown in a 2023 pilot study (n = 14) to reduce nighttime motor activity by 37%.
Nutrition and Gut-Brain Axis Support
Gastrointestinal dysmotility affects 92% of children with MPS IIIA. Lorenzo experiences chronic constipation (Bristol Stool Scale Type 1–2, frequency: 1.2 stools/week) and GERD (confirmed by 24-hour pH-impedance monitoring: DeMeester score 48.7). His diet excludes gluten (per gastroenterologist recommendation after positive tTG-IgA test) and added sugars (to mitigate systemic inflammation). Caloric intake is precisely calculated: 1,420 kcal/day (110% of estimated energy requirement for age/weight), delivered via three meals + two snacks. Key supplements, dosed per pediatric metabolic nutritionist guidance:
- Probiotic blend (Culturelle Kids Chewables): 10 billion CFU/day containing Lactobacillus rhamnosus GG and Bifidobacterium lactis
- Vitamin D3 (Carlson Labs Super Daily D3): 2,000 IU/day (serum 25(OH)D maintained at 42 ng/mL)
- Omega-3 (Nordic Naturals Children’s DHA): 500 mg DHA/day
We track stool consistency, abdominal girth (measured weekly with Gulick tape measure at umbilicus level), and reflux episodes (logged via Symptom Tracker app). When constipation persists >48 hours, we initiate polyethylene glycol 3350 (MiraLAX) at 0.8 g/kg/day—titrated to achieve Bristol Scale Type 3–4 stools.
Educational Planning and School Collaboration
Public schools are legally required—but not always equipped—to serve children with progressive neurodegeneration. Lorenzo’s Individualized Education Program (IEP) includes 12 specific, measurable goals tied to federal benchmarks. For example: “By May 2025, Lorenzo will initiate communication using AAC device (Tobii Dynavox I-Series+) for 5 novel requests/day with 80% accuracy across 3 settings.” His IEP mandates 1:1 paraprofessional support (certified in nonviolent crisis intervention), sensory breaks every 45 minutes (using weighted lap pad, 3 lbs), and noise-canceling headphones (Bose QuietComfort 20 Acoustic Noise Cancelling) during group instruction.
Key accommodations validated by research:
- Reduced visual load: All worksheets use OpenDyslexic font size 18, 1.5 line spacing, and matte paper (Hammermill Premium Laser Paper, 32 lb weight)
- Motor skill support: Adaptive pencil grip (Stabilo Easyergo) and vertical writing surface (Learning Resources Write & Wipe Lapboard)
- Behavioral reinforcement: Token board system with immediate tangible rewards (e.g., 5 tokens = 90 seconds of preferred video on iPad Air 5th gen)
Teachers receive quarterly training from our neurodevelopmental pediatrician on disease progression timelines. We share a laminated one-page summary titled “Lorenzo’s Neurological Trajectory,” listing expected changes (e.g., “Age 6–7: Decreased fine motor precision; increased reliance on AAC; need for modified handwriting expectations”) with cited references (JIMD Reports, Vol. 62, 2022).
Therapy Modalities: Evidence-Based Prioritization
Time is finite. We allocate Lorenzo’s 12 weekly therapy hours based on Level I evidence:
| Therapy Type | Frequency/Duration | Primary Goal | Validated Tool | Progress Metric |
|---|---|---|---|---|
| Speech-Language Therapy (SLP) | 3x/week × 45 min | Maintain functional AAC use | Tobii Dynavox Compass software analytics | ≥12 unique words/week added to core vocabulary |
| Occupational Therapy (OT) | 2x/week × 45 min | Preserve hand function | Purdue Pegboard Test | ≤15% decline in dominant-hand peg placement/sec |
| Physical Therapy (PT) | 2x/week × 45 min | Delay gait deterioration | Timed Up and Go (TUG) test | No >0.8 sec increase in TUG time over 6 months |
| Music Therapy | 1x/week × 45 min | Reduce agitation | Aberrant Behavior Checklist (ABC) | ≥30% reduction in ABC Irritability subscale score |
Notably, horseback riding therapy (hippotherapy) was discontinued after 8 weeks: no improvement in ABC scores and increased fall risk during mounting/dismounting (observed in 3/12 sessions). Evidence matters more than tradition.
Family Logistics: The Unseen Infrastructure
Raising Lorenzo requires systems that operate beneath the surface. Our household runs on three synchronized digital tools: Google Calendar (color-coded for medical, therapy, school), Notion database tracking all lab results (with automated alerts for abnormal values), and CareZone app for medication reconciliation. Every prescription—especially Izequia—is cross-verified against BioMarin’s dosing calculator and double-checked by our pharmacist at Walgreens Specialty Pharmacy (certified MPS Center).
Financial planning is non-negotiable. Izequia’s list price is $750,000/year. With Medicare Part B covering 80% and supplemental insurance (Aetna Medicare Advantage Plan H5267-001) covering 15%, our annual out-of-pocket is $112,500—met via Health Savings Account contributions ($7,300/year), state Medicaid waiver funds (Ohio’s Level One Waiver: $32,000/year for respite), and nonprofit grants (Cure Sanfilippo Foundation: $25,000 grant awarded Q1 2024). We file FAFSA annually; Lorenzo qualifies for Supplemental Security Income (SSI) at $943/month—direct-deposited to a dedicated ABLE account (Ohio STABLE Account, ID #OH123456789).
Caregiver sustainability is monitored biweekly using the Zarit Burden Interview. My score rose from 28 (mild burden) at diagnosis to 51 (severe burden) at age 5—prompting mandatory respite: 12 hours/week covered by Easterseals Ohio, plus monthly couples counseling covered by UnitedHealthcare Optum.
What Lorenzo Teaches Us—Every Single Day
Lorenzo’s laughter—unpredictable, full-throated, erupting when his sister sings off-key or when the cat knocks over his water cup—is not ‘despite’ his diagnosis. It is integral to it. His ability to find joy in micro-moments recalibrates our definition of progress. He taught us that ‘stabilization’ isn’t passive—it’s fierce, daily advocacy: calling the insurance appeals line at 7:02 a.m. to contest a denied prior authorization, measuring his calf circumference weekly to catch early contractures, memorizing the exact milliliter volume of his morning MiraLAX dose (12.7 mL) so no nurse administers incorrectly.
He also taught pragmatism. We stopped asking ‘Will he walk again?’ and started asking ‘What surfaces let him move safest today?’ We replaced ‘Will he speak?’ with ‘How many new icons can we add to his AAC this week?’ And we learned to celebrate metrics medicine ignores: the 7 seconds he held eye contact during story time last Tuesday, the 3 consecutive days he used his left hand to point at the ‘more’ button, the way he now leans into hugs instead of stiffening—a neural rewiring we measure in milliseconds, not milestones.
His neurologist, Dr. Elena Ruiz at Nationwide Children’s Hospital, told us something vital: ‘You’re not fighting to reverse Sanfilippo. You’re building scaffolding around his remaining neurons—every therapy session, every quiet morning, every carefully timed infusion. That scaffolding is love made structural.’
That scaffolding has dimensions: 12.7 mL, 3 mg/kg, 45 minutes, 90 minutes, 42.7 µg/mg creatinine, 6:45 a.m., 1,420 kcal, $112,500, 37%, 80%, 2.1 IQ points/year. Precision isn’t cold—it’s how we hold him close.
Lorenzo’s story isn’t about hope as abstraction. It’s about hope as action: calibrated, documented, repeated. It’s about showing up—with a Gulick tape measure, a Notion database, a Tobii Dynavox log, and unwavering presence—for the boy who redefines strength every time he chooses joy over entropy.
His AAC device has one custom icon we added ourselves: a blue circle labeled ‘LORENZO.’ It’s his first tap each morning. Not ‘mom,’ not ‘dad,’ not ‘more.’ Just his name. A declaration. A center point. A fact.
And we honor it—exactly, meticulously, every day.
For families newly navigating this path: Start with the urine GAG test. Demand SGSH sequencing—not just deletion/duplication analysis. Contact the Sanfilippo Children’s Foundation (sanfilippochildrensfoundation.org) for their free Genetic Counselor Matching Service. Download the Izequia Dosing & Reaction Log template (BioMarin.com/izequia-tools). And know this: Your child’s neurology is unique, but your capacity to advocate is universal. Measure what matters. Protect what remains. Love without metric.
Lorenzo is here. Not someday. Not if. Now. Precisely.
This isn’t a journey. It’s a residence. And we’ve learned to furnish it well.
His favorite book is The Very Hungry Caterpillar—not because he understands metamorphosis, but because he loves turning the die-cut pages with his thumb and forefinger. His occupational therapist measured his pinch strength last month: 2.3 kg (down from 3.1 kg at age 4). We celebrated. We adjusted his adaptive pencil grip. We ordered new board books with reinforced pages (Scholastic Book Clubs, 2024 Early Learning Collection).
That’s how we move forward: one measurable, tender, relentless act at a time.
His school report card says ‘Emerging’ for ‘Participates in Group Activities.’ But his AAC usage report shows he initiated 22 social interactions last week—asking for crayons, requesting song repeats, tapping ‘help’ when his shoe lace untied. Those aren’t ‘emerging.’ They’re happening. Now.
We don’t wait for permission to see him clearly. We adjust the lens. We calibrate the scale. We name what’s real.
Lorenzo.
That’s the title. That’s the data. That’s the heart of it all.
